# Galux

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/galux

- Industry: Pharmaceuticals
- Headquarters: Seoul, South Korea
- Website: www.galux.co.kr
- Total disclosed funding: $32M
- Latest round: Series B (Feb 9, 2026)
- Investors on record: 14

## About

Galux Inc., founded in 2020, is headquartered in Seoul, South Korea, and focuses on the innovative field of drug discovery. In February 2026, Galux Inc. raised KRW 42 billion in series B funding from new investors Yuanta Investment, Korea Development Bank, NH Investment & Securities, TKG Ventures, SL Investment, NCORE Ventures, Sneak Peek Investment, Korea Investment & Securities, and Mirae Asset Securities. Returning investors InterVest, DAYLI Partners, and Pathway Investments also participated in this round.

Galux specializes in in silico drug discovery, leveraging an integrated technology platform that combines principles from physics, chemistry, and artificial intelligence to enhance the drug development process. The cornerstone of Galux's offerings is the GALAXY protein structure modeling platform, recognized as one of the leading methods globally, validated through comparative studies like CASP and CAPRI. By enabling precise modeling of protein structures, Galux's solutions aim to address critical challenges in drug design, including target identification and optimization of lead compounds. The company's client base primarily includes pharmaceutical and biotechnology companies that seek to expedite their drug discovery pipeline, with a focus on markets such as North America, Europe, and Asia.
Galux generates revenue through various business models tailored to the needs of its clients. The primary structure comprises partnerships and subscription-based access to its GALAXY modeling platform, allowing clients to utilize advanced computational tools for drug discovery. Clients engage with Galux on a contractual basis, where they can access specific services or software licensing for a set period, facilitating ongoing support and updates. Transaction models are designed to accommodate both small biotech firms and larger pharmaceutical companies, ensuring scalability in their offerings. While specific pricing details remain undisclosed, the revenue streams are expected to be aligned with the high value placed on innovative solutions in the competitive pharmaceutical landscape.
The company will use the February 2026 funding to advance its artificial intelligence platform technology, expands research and development infrastructure, secure key personnel, and conduct non-clinical validation of new drug candidates.

## Funding rounds

- Series B, Feb 9, 2026, $29M — Korea Development Bank, Korea Investment & Securities, InterVest, SL Investment, Yuanta Investment, NH Investment & Securities, NCORE Ventures, DAYLI Partners, Mirae Asset Securities, Sneak Peek Investment, TKG Ventures, Pathway Investments
- Series A, Jul 12, 2022, $3.1M — Loftyrock Investment, Pathway Partners

## Investors

- Loftyrock Investment (https://capitalatlas.ai/funds/loftyrock-investment) — Series A
- Pathway Partners (https://capitalatlas.ai/funds/pathway-partners) — Series A
- Korea Development Bank (https://capitalatlas.ai/funds/korea-development-bank) — Series B
- Korea Investment & Securities (https://capitalatlas.ai/funds/korea-investment-securities) — Series B
- InterVest (https://capitalatlas.ai/funds/intervest) — Series B
- SL Investment (https://capitalatlas.ai/funds/sl-investment) — Series B
- Yuanta Investment (https://capitalatlas.ai/funds/yuanta-investment) — Series B
- NH Investment & Securities (https://capitalatlas.ai/funds/nh-investment-securities) — Series B
- NCORE Ventures (https://capitalatlas.ai/funds/ncore-ventures) — Series B
- DAYLI Partners (https://capitalatlas.ai/funds/dayli-partners) — Series B
- Mirae Asset Securities (https://capitalatlas.ai/funds/mirae-asset-securities) — Series B
- Sneak Peek Investment (https://capitalatlas.ai/funds/sneak-peek-investment) — Series B
- TKG Ventures (https://capitalatlas.ai/funds/tkg-ventures) — Series B
- Pathway Investments — Series B